Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Moodys
Colorcon
McKinsey
Johnson and Johnson

Last Updated: August 15, 2022

MEGACE ES Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Megace Es, and when can generic versions of Megace Es launch?

Megace Es is a drug marketed by Endo Pharms Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-six patent family members in nineteen countries.

The generic ingredient in MEGACE ES is megestrol acetate. There are eighteen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the megestrol acetate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Megace Es

A generic version of MEGACE ES was approved as megestrol acetate by STRIDES PHARMA on August 8th, 1988.

  Try it Free

Paragraph IV (Patent) Challenges for MEGACE ES
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
MEGACE ES Oral Suspension megestrol acetate 125 mg/mL 021778 1 2011-04-27

US Patents and Regulatory Information for MEGACE ES

MEGACE ES is protected by five US patents.

Patents protecting MEGACE ES

Nanoparticulate megestrol formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

Nanoparticulate megestrol formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

Nanoparticulate megestrol formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

Nanoparticulate megestrol formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

Nanoparticulate megestrol formulations
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for MEGACE ES

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 See Plans and Pricing See Plans and Pricing
Endo Pharms Inc MEGACE ES megestrol acetate SUSPENSION;ORAL 021778-001 Jul 5, 2005 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for MEGACE ES

See the table below for patents covering MEGACE ES around the world.

Country Patent Number Title Estimated Expiration
Argentina 072135 FORMAS DE DOSIFICACION DE FENOFIBRATO See Plans and Pricing
Spain 2359298 See Plans and Pricing
Hungary 208497 X-RAY-CONTRAST COMPOSITIONS FOR PRODUCING MEDICAL PICTURES See Plans and Pricing
Australia 2003230692 NANOPARTICULATE COMPOSITIONS OF MAP KINASE INHIBITORS See Plans and Pricing
Japan 2011251989 LOW VISCOSITY LIQUID DOSAGE FORM See Plans and Pricing
World Intellectual Property Organization (WIPO) 03103640 See Plans and Pricing
Germany 60319073 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
AstraZeneca
Baxter
Express Scripts
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.